Benefits
Reduced menopausal vasomotor symptoms
Heyerick 2006 — first prospective, randomized, double-blind, placebo-controlled study of standardized hop extract for menopausal discomfort. 100 μg 8-PN/day reduced hot flashes, night sweats, and overall menopausal discomfort scores significantly vs placebo over 12 weeks. Effects emerged at 4 weeks and accumulated through 12 weeks.
Bone mineral density preservation
Lecomte 2023 — 1-year RCT in 100 osteopenic postmenopausal women (50 hop extract + CaD vs 50 placebo + CaD). Total body BMD increased 1.8% from baseline in active group (p<0.0001) and 1.0% greater than placebo (p=0.08). Higher proportion of women experiencing positive BMD changes vs placebo.
Sexual dysfunction improvement
Vahedpoorfard 2023 — RCT in 63 postmenopausal women with sexual dysfunction comparing hop extract vs estradiol over 12 weeks. Hop extract significantly improved sexual function indices, supporting use as an alternative to estrogen therapy in women who cannot or prefer not to use estradiol.
Estrogen metabolism modulation toward favorable pathway
Hop extract and 6-PN preferentially induce the P450 1A1 catalyzed 2-hydroxylation pathway of estrogen metabolism (vs the 4-hydroxylation pathway via P450 1B1). The 2-hydroxylation pathway produces less genotoxic metabolites, theoretically reducing breast cancer risk associated with estrogen exposure.
Gut microbiome modulation
Lecomte 2023 documented gut microbiome composition changes and increased short-chain fatty acid (SCFA) production with hop extract supplementation. The microbiome may play a role in 8-PN bioactivation (intestinal bacteria can convert isoxanthohumol to active 8-PN), suggesting individual response variation may correlate with gut microbiome composition.
Mechanism of action
Estrogen receptor binding (most potent natural phytoestrogen)
8-prenylnaringenin (8-PN) is the most potent phytoestrogen identified — receptor binding affinity exceeds coumestrol, genistein, daidzein, and other established phytoestrogens. Binds both ERα and ERβ. The high potency allows clinically meaningful effects at low doses (100 μg/day) compared to gram-quantity doses needed for soy isoflavones.
Osteoblast/osteoclast bone modulation
In vitro, 8-PN enhances osteoblast differentiation and maturation (bone-building cells) while inhibiting osteoclast differentiation (bone-resorbing cells) — both effects of intensities exceeding soy isoflavones. Animal models confirm bone biomechanical property preservation in ovariectomized rats at intensities comparable to estradiol.
Hot flash mechanism via thermoregulation
Ban 2018 ovariectomized rat model — Lifenol hop extract attenuated forced running-induced dermal and rectal temperature rises and modulated blood flow velocity, providing a mechanistic basis for vasomotor symptom relief beyond simple estrogen receptor activation.
Clinical trials
Double-blind, placebo-controlled, randomized trial (Lecomte, Tomassi, Rizzoli, Tenon, Berton, Harney, Fança-Berthon 2023, Nutrients 15(12):2688).
100 postmenopausal osteopenic women (>1 year post-menopause), aged 50-85 years, BMI 18-32, randomized 1:1 to Lifenol® (100 μg 8-PN/day, n=50) or placebo (n=50). Both groups received calcium 1000 mg + vitamin D3 800 IU daily for 48 weeks.
48-week supplementation increased total body BMD (1.8 ± 0.4% from baseline, p<0.0001; 1.0 ± 0.6% greater than placebo, p=0.08). Higher proportion of women experienced positive BMD changes in active vs placebo group. Gut microbiome composition shifts and increased SCFA levels documented. Quality of life (SF-36) improved. No serious adverse events. Established Lifenol® as a non-hormonal option for bone health support in postmenopausal osteopenia.
Prospective, randomized, double-blind, placebo-controlled study (Heyerick, Vervarcke, Depypere, Bracke, De Keukeleire 2006, Maturitas 54(2):164-75).
67 menopausal women experiencing hot flashes and other menopausal discomforts, randomized to placebo, hop extract delivering 100 μg 8-PN/day, or hop extract delivering 250 μg 8-PN/day, over 12 weeks (2 cycles).
All groups including placebo showed significant Kupperman Index reductions at 6 and 12 weeks. The 100 μg 8-PN dose was significantly superior to placebo at week 6 (p=0.023) BUT the superiority was no longer statistically significant at week 12 (p=0.086). Counterintuitively, the higher 250 μg dose was less active than the lower dose at both time points — no dose-response relationship could be established. Authors framed this as preliminary evidence of menopausal symptom relief; the effect window appears concentrated in the first 6-8 weeks of supplementation.
Randomized, double-blind, placebo-controlled trial (Estrugo, Rodríguez, de Guevara, Gómez, Ridocci, Moro-Martín, Guinot, Saz-Leal, Nieto Magro 2023, J Menopausal Med 29(2):73-83).
Postmenopausal women with menopausal symptoms randomized to standardized hop extract enriched in 8-PN or placebo.
Reduction in menopausal symptoms with hop extract supplementation, supporting the 2006 Heyerick findings with a more recent independent trial. Adds confirmatory evidence to the menopausal symptom relief claim.
About this ingredient
Lifenol® is a polyphenolic powdered extract obtained by a patented supercritical CO₂ extraction process from female hop flowers (Humulus lupulus L.), followed by ethanol extraction. Originally developed by Naturex (Avignon, France) and now part of Givaudan. Standardized to 8-prenylnaringenin (8-PN) content — typically delivering 100 μg 8-PN per daily dose.
8-PN is the most potent phytoestrogen identified to date — receptor binding affinity exceeds coumestrol, genistein, daidzein, and other studied phytoestrogens. Other active prenylflavonoids include 6-prenylnaringenin (6-PN), isoxanthohumol (IX), and xanthohumol (XH). Notably, intestinal bacteria can convert isoxanthohumol to active 8-PN, contributing to inter-individual response variation.
Lifenol® was a 2025 NutraIngredients Awards finalist in the women's healthy aging category. EVIDENCE: Three published RCTs — Heyerick 2006 (foundational menopause, n=67), Lecomte 2023 (1-year bone, n=100), and Estrugo 2023 (menopause confirmation). The Vahedpoorfard 2023 trial of broader hop extract (not Lifenol-specific) supports sexual dysfunction benefit.
Strong preclinical mechanism evidence (Ban 2018 OVX rat model, multiple in vitro studies). 2/5 evidence rating reflects modest trial count and mostly manufacturer-funded research, despite favorable results. The 1-year bone trial is methodologically strong but the placebo-comparison missed conventional statistical significance for BMD (p=0.08) — encouraging but not definitive.
SAFETY: Generally well-tolerated. Hormone-sensitive cancers and concurrent HRT are absolute contraindications due to potent phytoestrogen activity. Effects emerge at 4-6 weeks for vasomotor symptoms, accumulate over months for bone outcomes.
Best positioned as a non-hormonal option for women with mild-to-moderate menopausal symptoms or osteopenia who cannot or prefer not to use estradiol — set expectations: hot flash reductions are real but partial, and bone benefits require 6-12 months for measurable BMD changes.